Rheumatology

Journal

Publication Venue For

  • The changing epidemiology of inpatient gout and associated mortality: a 17-year national study. 2020
  • Which factors predict discordance between a patient and physician on a gout flare? 2020
  • Total knee arthroplasty outcomes in lupus: A study using the US National Inpatient Sample.  58:2130-2136. 2019
  • Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase.  58:1422-1431. 2019
  • Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.  58:1259-1267. 2019
  • Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.  58:874-883. 2019
  • Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.  58:61-69. 2019
  • How to use bisphosphonates safely and optimally.  57:1875-1876. 2018
  • Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.  57:677-687. 2018
  • Allopurinol and the risk of incident peripheral arterial disease in the elderly: A us medicare claims data study.  57:451-461. 2018
  • Any sleep is a dream far away: A nominal group study assessing how gout affects sleep.  57:1925-1932. 2018
  • Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study.  56:2170-2178. 2017
  • Enrichment of malondialdehyde-acetaldehyde antibody in the rheumatoid arthritis joint.  56:1794-1803. 2017
  • More than meets the eye: IgG4-related disease presenting as isolated interstitial lung disease.  56:1630-1631. 2017
  • Racial differences in health-related quality of life and functional ability in patients with gout.  56:103-112. 2017
  • A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis.  55:1106-1111. 2016
  • Performance of Gout Impact Scale in a longitudinal observational study of patients with gout.  55:982-990. 2016
  • Disease features and outcomes in United States lupus patients of hispanic origin and their mestizo counterparts in latin America: A commentary.  55:436-440. 2016
  • The frequency and outcome of lupus nephritis: Results from an international inception cohort study.  55:252-262. 2015
  • Circulating naive and memory CD4+ T cells and metabolic syndrome in patients with systemic lupus erythematosus: Data from a primarily Mestizo population.  54:1302-1307. 2015
  • Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality.  54:1587-1595. 2015
  • Remission of rheumatoid arthritis on brentuximab vedotin.  53:2314-2315. 2014
  • Patient-level improvements in pain and activities of daily living after total knee arthroplasty.  53:313-320. 2014
  • Underlying diagnosis predicts patient-reported outcomes after revision total knee arthroplasty.  53:361-366. 2014
  • Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty.  53:1752-1758. 2014
  • Primary cardiac disease in systemic lupus erythematosus patients: Protective and risk factors-data from a multi-ethnic Latin American cohort.  53:1431-1438. 2014
  • Expression of cathepsin K and tartrate-resistant acid phosphatase is not confined to osteoclasts but is a general feature of multinucleated giant cells: Systematic analysis.  52:1529-1533. 2013
  • Patient-level clinically meaningful improvements in activities of daily living and pain after total hip arthroplasty: Data from a large US institutional registry.  52:1109-1118. 2013
  • Medical and psychological comorbidity predicts poor pain outcomes after total knee arthroplasty.  52:916-923. 2013
  • Safety and efficacy of intra-articular infliximab therapy for treatment-resistant temporomandibular joint arthritis in children: A retrospective study.  52:554-559. 2013
  • Anti-malarials exert a protective effect while mestizo patients are at increased risk of developing SLE renal disease: Data from a Latin-American cohort.  51:1293-1298. 2012
  • Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis.  50:2223-2232. 2011
  • Minimally important differences of the gout impact scale in a randomized controlled trial.  50:1331-1336. 2011
  • Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: Case series with 12 patients.  50:417-419. 2011
  • Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII).  49:1720-1725. 2010
  • Predictors of cardiovascular damage in patients with systemic lupus erythematosus: Data from LUMINA (LXVIII), a multiethnic US cohort.  48:817-822. 2009
  • Perceptions of disease and health-related quality of life among patients with gout.  48:582-586. 2009
  • Renal damage is the most important predictor of mortality within the damage index: Data from LUMINA LXIV, a multiethnic US cohort.  48:542-545. 2009
  • Health care utilization in patients with spondyloarthropathies.  48:272-276. 2009
  • Can patients help with long-term total knee arthroplasty surveillance? Comparison of the American Knee Society Score self-report and surgeon assessment.  48:160-164. 2009
  • Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico..  48:1392-1397. 2009
  • Validity of physician-reported hospitalized infections in a US arthritis registry..  48:1269-1272. 2009
  • Health-related quality of life in veterans with prevalent total knee arthroplasty and total hip arthroplasty.  47:1826-1831. 2008
  • Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus - Results from LUMINA (LIX): A multiethnic US cohort.  47:1093-1096. 2008
  • Use of rituximab for the treatment of rheumatoid arthritis: The Latin American context.  47:1097-1099. 2008
  • Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort.  47:362-367. 2008
  • Assessment of outcome in clinical trials of gout - A review of current measures.  46:1751-1756. 2007
  • Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual.  46:1471-1476. 2007
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: Factors predictive of new or worsening proteinuria.  46:683-689. 2007
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonists.  46:1688-1693. 2007
  • Predictors of post-partum damage accrual in systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (XXXVIII).  45:1380-1384. 2006
  • Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII)..  45:1380-1384. 2006
  • The spectrum of renal tubular acidosis in paediatric Sjögren syndrome.  45:85-91. 2006
  • Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events.  44:1303-1307. 2005
  • Lack of recording of systemic lupus erythematosus in the death certificates of lupus patients.  44:1186-1189. 2005
  • Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD).  44:1038-1042. 2005
  • Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: Association between C-reactive protein (CRP) gene polymorphisms and vascular events.  44:864-868. 2005
  • The cost of glucocorticoid-associated adverse events in rheumatoid arthritis.  44:781-788. 2005
  • Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.  43:358-363. 2004
  • Systemic lupus erythematosus and gouty arthritis: An uncommon association.  43:349-352. 2004
  • Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage.  43:202-205. 2004
  • Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone.  42:989-994. 2003
  • Systemic lupus erythematosus - Messages from experimental models.  39:18-27. 2000
  • Adverse events in methotrexate-treated rheumatoid arthritis patients.  34:49-56. 1995
  • Adverse events in methotrexate-treated rheumatoid arthritis patients.  34:49-56. 1995
  • Clinical conundrum.  29:283. 1990
  • International Standard Serial Number (issn)

  • 1462-0324
  • Electronic International Standard Serial Number (eissn)

  • 1462-0332